1. Shi, Chang-He, Mao, Cheng-Yuan, Zhang, Shu-Yu, Zhuang, Zheng-Ping, Xu, Yu-Ming. 2015. CHCHD2 gene mutations in familial and sporadic Parkinson's disease. In Neurobiology of aging, 38, 217.e9-217.e13. doi:10.1016/j.neurobiolaging.2015.10.040. https://pubmed.ncbi.nlm.nih.gov/26705026/
2. Leventoux, Nicolas, Morimoto, Satoru, Ishikawa, Mitsuru, Kokubo, Yasumasa, Okano, Hideyuki. 2024. Aberrant CHCHD2-associated mitochondriopathy in Kii ALS/PDC astrocytes. In Acta neuropathologica, 147, 84. doi:10.1007/s00401-024-02734-w. https://pubmed.ncbi.nlm.nih.gov/38750212/
3. Li, Yue, Xiu, Wenjing, Xu, Jingwen, Wang, Qi, Wang, Chunjiong. 2022. Increased CHCHD2 expression promotes liver fibrosis in nonalcoholic steatohepatitis via Notch/osteopontin signaling. In JCI insight, 7, . doi:10.1172/jci.insight.162402. https://pubmed.ncbi.nlm.nih.gov/36477358/
4. Lumibao, Jan C, Haak, Payton L, Kolossov, Vladimir L, Steelman, Andrew J, Gaskins, H Rex. 2023. CHCHD2 mediates glioblastoma cell proliferation, mitochondrial metabolism, hypoxia‑induced invasion and therapeutic resistance. In International journal of oncology, 63, . doi:10.3892/ijo.2023.5565. https://pubmed.ncbi.nlm.nih.gov/37654190/